Table 1. Patient characteristics and clinical features.
| patient | age | gender | stadium | Ig-type | time since diagnosis (months) | prior therapies |
|---|---|---|---|---|---|---|
| 1 | 65 | f | III B | IgG kappa | 27 | HD-Melphalan + ABSCT |
| 2 | 61 | m | II B | IgG kappa | 22 | 3x HD-Melphalan + ABSCT, RAD, VCD |
| 3 | 55 | m | III B | IgG kappa | 2 | 0 |
| 4 | 67 | f | III A | IgA lambda | 3 | Dexa, VCD |
| 5 | 77 | m | II A | IgG kappa | 82 | Melphalan-Prednisone, RD, MPV, BPT, VCD, PAD |
| 6 | 73 | f | III B | IgA kappa | 0 | 0 |
| 7 | 75 | f | III A | IgG kappa | 73 | Dexa, 2x HD-Melphalan + ABSCT, AUY + Bortezomib, BPT, RD, 1x HD-Melphalan + ABSCT, RD |
| 8 | 87 | m | III B | IgG kappa | 20 | Melphalan + Prednisone |
| 9 | 59 | m | III B | IgG kappa | 27 | PAD, 1x HD-Melphalan + ABSCT, Revlimid |
ABSCT: autologous stem cell transplantation
AUY: NVP-AUY922
BPT: bortezomib, prednisone and thalidomide
Dexa: dexamethasone
HD-Melphalan: high dose melphalan
MPV: melphalan, prednisone and bortezomib
PAD: prednisone, adriamycin and dexamethasone
RAD: revlimid, adriamycin and dexamethasone
RD: revlimid and dexamethasone
VCD: bortezomib, cyclophosphamide and dexamethasone